Zsolt Bosnyak, MD, PhD
Global Medical Head of the Insulins Franchise and Diabetes Solution, Sanofi, France
Dr. Zsolt Bosnyak is the Global Medical Head of the Insulins Franchise and Diabetes Solution at Sanofi’s headquarters in Paris. He has more than 20 years of diabetes clinical, research, and pharmaceutical experience.
Dr. Bosnyak’s responsibilities at Sanofi include leadership on Sanofi’s global medical strategies, late phase clinical research (Phase 3-4), and a unique complementary real-world evidence program to look for new approaches in the understanding of diabetes outcomes in real-life settings. Previously, he held various medical and clinical development positions at Pfizer, Novo Nordisk, and Ferring Pharmaceuticals in the therapeutics area of diabetes/metabolism, endocrinology, cardiovascular disease, and urology/oncology.
Before joining the pharmaceutical industry, Dr. Bosnyak was a postdoctoral fellow of the American Diabetes Association at the University of Pittsburgh School of Public Health, Department of Epidemiology. He was involved in large-scale international prospective studies in the field of type 1 diabetes mortality and complications and later received his PhD in this field. He worked as a clinician and researcher in collaboration with various large diabetes/metabolism centers (including National Centre for Diabetes Care, Hungary, and Steno Diabetes Centre, Denmark) in the areas of type 1 diabetes, type 2 diabetes, and gestational diabetes mellitus. His key publications cover the fields of epidemiology of diabetes complication, cardiovascular outcomes, insulin therapy and related real-world evidence.
Dr. Bosnyak obtained his MD at the Semmelweis University in Budapest. He is a board-certified internist and licensed diabetologist with a diploma in pharmaceutical medicine.